Advertisement

Topics

Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)

09:58 EDT 1 Aug 2017 | Instinctif Partners

Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement

LONDON, BOSTON, SAN FRANCISCO, TOKYO (August 1, 2017) — According to life science commercial intelligence firm, Evaluate, the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.

The prices of Gilead’s hepatitis C virus (HCV) blockbusters Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS’ novel PD-1/PD-L1 agent.

However, the sales decline of marketed products is counterbalanced by the optimism surrounding new therapies coming to market expected to account for 34% of sales in 2022, among the top ranking are Dupixent (Sanofi), Ibrance (Pfizer), Entresto (Novartis), Aducanumab (Biogen), and Emicizumab (Chugai).

Evaluate recently launched consensus drug forecasts for the Japanese market revealing new insights on the future outlook of the country’s Pharma & Biotech sector for benchmarking and market analysis.  For more information and to download the topline marketed and R&D forecast to 2022 in Yen and USD visit: www.evaluate.com/JapanDrugForecasts.

About Evaluate

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epvantage.  On Instagram: Evaluateltd.

Issued for and on behalf of Evaluate Ltd by Instinctif Partners.

For more information please contact: Evaluate and EP Vantage (for general questions) Christine Lindgren +1 617-866-3906 christine.lindgren@evaluategroup.com Instinctif Partners (for non-U.S. media) Gemma Harris/Melanie Toyne Sewell +44 (0) 20 7457 2020 evaluate@instinctif.com Jani Communications (for U.S. media) Janice Foley +1-617-823-5555 janifoley@verizon.net Edelman Japan KK (For Japanese media) Yamada/Masaki TEL: +81(3)-4360-9000 evaluatejapanpr@edelman.com NEXT ARTICLE

More From BioPortfolio on "Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)"

Quick Search
Advertisement
 

Relevant Topic

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...